Udhayvir Grewal, GI Oncologist at Winship Cancer Institute of Emory University, shared a post on X:
“Intriguing data from MDACC – neoadjuvant CAPTEM in locally advanced or metastatic PanNETs. ORR was only 6.%, tumor vessel involvement was modified from >180° to ≤180° in only 16.%. No statistically significant shift in TVI with treatment. Four patients had a change from an unresectable primary tumor to an anatomically resectable tumor following CAPTEM.
A little surprised by these data knowing CAPTEM works fairly well in the metastatic disease setting. 40% ORR. It has worked well in a handful of cases where I have used it for with neoadjuvant intent. Unsure if MGMT testing would help select candidates in this space.
Title: Primary Tumor Size and Tumor–Vessel Interface Following Capecitabine and Temozolomide for Pancreatic Neuroendocrine Tumor
Authores: Jin Guo, Kever A Lewis, Laura Prakash, Priya Bhosale, Ajaykumar Morani, Matthew H G Katz, Ching-Wei D Tzeng, Naruhiko Ikoma, Rebecca Snyder, Michael P Kim, Chandrikha Chandrasekharan, Arvind Dasari, James C Yao, Jeffrey E Lee, Jessica E Maxwell, Daniel M Halperin.
Other articles featuring Udhayvir Grewal on OncoDaily.